# BrainsWay Ltd. (BWAY) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $11.15, market value $449 million.

## Valuation
- **P/E (trailing): 48.5×** (5-yr avg 94.3×, 3-yr avg 94.3×). BrainsWay Ltd. trades at 48.5× trailing earnings, well below its own five-year average of 94.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.0×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 7.4×**. Each dollar of revenue is priced at 7.4×.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 28.5×**. Enterprise value is 28.5× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.3%** (5-yr avg 1.5%). Free cash flow equals 1.3% of the market value, in line with its five-year average of 1.5%.
- **Earnings yield: 2.1%**. The inverse of the P/E: 2.1% of the price is earned each year.

## Profitability
- **Gross margin: 75.3%**. BrainsWay Ltd. keeps 75.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 12.5%**. 12.5% of revenue is left after running the business.
- **Net margin: 14.6%**. 14.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.4%**. 10.4% on shareholders' equity is solid.
- **Return on invested capital: 68.1%**. Return on all capital, debt included, is 68.1%: comfortably above what that capital costs.
- **Return on assets: 8.4%**. Each dollar of assets produces 8.4% of profit.

## Growth
- **Revenue growth (1 yr): 27.3%** (3-yr 24.3%/yr, 5-yr 18.8%/yr). Revenue grew 27.3% over the last year, against 18.8% a year compounded over five years: growth is accelerating.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BrainsWay Ltd. holds more cash than debt.
- **Interest coverage: 3.4×**. Operating profit covers interest 3.4× over, a safe margin.
- **Current ratio: 3.83** (quick 3.51). Current assets cover the next year's liabilities 3.83 times.
- **Altman Z-score: 8.95**. A Z-score of 8.95 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BrainsWay Ltd. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover BrainsWay Ltd.; the consensus is strong_buy, with an average price target of $19.27 (+73% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.6%** (YTD 16.6%, 3-mo -29.9%). The shares are up 31.6% over twelve months including dividends.
- **From 52-week high: -35.9%** (56.3% above the low). Trading 36% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 1.98** (volatility 54%). Beta of 1.98 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BWAY · Page: https://foliofundamentals.com/stocks/bway

Not investment advice.